Keytruda (Pembrolizumab) Receives FDA Supplemental Approval for Efficacy

The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on August 5, 2016. This approval, designated BLA 125514 S-9, specifically addresses the efficacy of the drug.

Background

Pembrolizumab, marketed as Keytruda by Merck Sharp Dohme, is a well-established therapeutic agent. This supplemental approval, categorized as an 'efficacy' class approval, specifically relates to data supporting the drug's effectiveness. Supplemental applications are a standard part of the drug lifecycle for approved medications, often submitted to update existing information, add new indications, or refine dosing. In this particular instance, the focus of the supplemental application is explicitly on additional efficacy data, indicating a review of new evidence supporting its therapeutic benefits.

What this means

This supplemental approval for Keytruda (pembrolizumab) on August 5, 2016, signifies that the FDA has thoroughly reviewed and accepted additional data supporting the drug's effectiveness. Such approvals are a critical part of the post-market regulatory process, ensuring that the scientific understanding of a drug's performance evolves as new data becomes available. While the specific details of the new efficacy data or the context in which it was evaluated are not provided in this announcement, these types of updates typically reinforce or expand the understanding of a drug's therapeutic benefits. For clinicians, this means that the FDA has found further evidence to support Keytruda's ability to produce the desired therapeutic effect. This could lead to updated prescribing information or further confidence in its use within its approved indications, based on the newly accepted efficacy information. Researchers and patient advocates can note this as an official update to the drug's regulatory profile, reflecting ongoing evaluation of its performance and safety through the BLA process.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125514 S-9 was documented on August 5, 2016, on accessdata.fda.gov.